Freestone Grove Partners LP Invests $7.10 Million in Celcuity, Inc. $CELC

Freestone Grove Partners LP acquired a new stake in Celcuity, Inc. (NASDAQ:CELC) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 67,907 shares of the company’s stock, valued at approximately $7,104,000.

Other large investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its holdings in Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the last quarter. US Bancorp DE grew its holdings in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the last quarter. Parallel Advisors LLC acquired a new position in Celcuity in the 1st quarter valued at approximately $38,000. Finally, Meeder Asset Management Inc. acquired a new position in Celcuity in the 4th quarter valued at approximately $42,000. Institutional investors own 63.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on CELC shares. Wall Street Zen lowered shares of Celcuity from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Leerink Partners set a $155.00 target price on Celcuity in a research report on Tuesday, June 2nd. Wells Fargo & Company cut their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Finally, Macquarie Infrastructure set a $160.00 price target on Celcuity in a research report on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Celcuity presently has a consensus rating of “Moderate Buy” and a consensus price target of $154.55.

Celcuity Stock Performance

Shares of Celcuity stock opened at $88.44 on Friday. The business has a 50-day moving average price of $94.64 and a two-hundred day moving average price of $107.15. Celcuity, Inc. has a 1-year low of $44.42 and a 1-year high of $151.02. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. The company has a market cap of $4.33 billion, a P/E ratio of -20.57 and a beta of 0.20.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). As a group, analysts anticipate that Celcuity, Inc. will post -4.75 EPS for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.